Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

IBC-Ab002

Alternative Names: IBC-Ab002, IBCAb002
Latest Update: 2025-01-23
Latest Update Note: Clinical Trial Update

Product Description

Humanized IgG1 antibody that inhibits an immune checkpoint protein called programmed death ligand, aka PD-L1, stimulating the immune system. (Sourced from: https://www.alzforum.org/therapeutics/ibc-ab002)

Mechanisms of Action: PD-L1 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Fortress Biotech
Company Location: NEW YORK NY 10014
Company CEO: Alexandra MacLean
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IBC-Ab002

Countries in Clinic: Israel, Netherlands, United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Alzheimer Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
IBC-01-01

P1

Active, not recruiting

Alzheimer Disease

2025-11-01

Recent News Events

Date

Type

Title

01/22/2024

News Article

 ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions